Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

The EMPA-REG outcome study: critical appraisal and potential clinical implications

(2016) Gianluca Perseghin et al.   Cardiovascular Diabetology

Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes

(2016) Karen S.L. Lam et al.   CURRENT MEDICAL RESEARCH AND OPINION

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies

(2016) Raktim Kumar Ghosh et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

(2016) Alan J. Sinclair et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

(2016) Deepson S Shyangdan et al.   BMJ Open

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial

(2015) Takashi Sasaki et al.   ADVANCES IN THERAPY

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

(2015) Hiroaki Iijima et al.   ADVANCES IN THERAPY

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

(2015) Norm Rosenthal et al.   Annals of the New York Academy of Sciences

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

(2015) Sunder Mudaliar et al.   DIABETES CARE

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:post hocsubgroup analyses according to body mass index in a 52-week open-label study

(2015) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure

(2015) Tetsushiro Takeuchi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

(2015) Jochen Seufert   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Greg L. Plosker   DRUGS

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

(2014)   PLoS One

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

(2014) Yoshihito Fujita et al.   Journal of Diabetes Investigation

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

(2014) Daniel Lorber   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

(2013) D. Polidori et al.   DIABETES CARE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury

(2008) Jarkko Piuhola et al.   CLINICAL SCIENCE